Applications of Cell-Penetrating Peptides for Tumor Targeting and Future Cancer Therapies

被引：116

作者：

Regberg, Jakob ^{[1
]}

Srimanee, Artita ^{[1
,2
]}

Langel, Ulo ^{[1
]}

机构：

[1] Stockholm Univ, Arrhenius Labs Nat Sci, Dept Neurochem, Svante Arrhenius Vag 21A, SE-10691 Stockholm, Sweden

[2] Mahidol Univ, Fac Pharm, Dept Pharmaceut Chem, Bangkok 10400, Thailand

来源：

PHARMACEUTICALS | 2012年 / 5卷 / 09期

关键词：

cell penetrating peptides; cancer; drug delivery; oligonucleotides; siRNA therapeutics; cell targeting peptides;

D O I：

10.3390/ph5090991

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Cell-penetrating peptides provide a highly promising strategy for intracellular drug delivery. One relevant clinical application of cell-penetrating peptides is cancer therapeutics. Peptide based delivery could increase the uptake of drugs in tumor cells and thereby increase the efficacy of the treatment, either of conventional small molecular drugs or oligonucleotide based therapeutics. This review is focused on the cancer applications of cell penetrating peptides as delivery systems; different aspects of drug loading, cargoes and delivery are discussed together with methods for targeted delivery, activatable cell-penetrating peptides and transducible agents coupled to cell-penetrating peptides.

引用

页码：991 / 1007

页数：17

共 59 条

[1] Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides
Aguilera, Todd A.
Olson, Emilia S.
Timmers, Margaret M.
Jiang, Tao
Tsien, Roger Y.
[J]. INTEGRATIVE BIOLOGY, 2009, 1 (5-6) : 371 - 381
[2] Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo
Andaloussi, Samir E. L.
Lehto, Taavi
Maeger, Imre
Rosenthal-Aizman, Katri
Oprea, Iulian I.
Simonson, Oscar E.
Sork, Helena
Ezzat, Kariem
Copolovici, Dana M.
Kurrikoff, Kaido
Viola, Joana R.
Zaghloul, Eman M.
Sillard, Rannar
Johansson, Henrik J.
Hassane, Fatouma Said
Guterstam, Peter
Suhorutsenko, Julia
Moreno, Pedro M. D.
Oskolkov, Nikita
Haelldin, Jonas
Tedebark, Ulf
Metspalu, Andres
Lebleu, Bernard
Lehtioe, Janne
Smith, C. I. Edvard
Langel, Uelo
[J]. NUCLEIC ACIDS RESEARCH, 2011, 39 (09) : 3972 - 3987
[3] Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: A comparative study
Aroui, Sonia
Brahim, Souhir
De Waard, Michel
Kenani, Abderraouf
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 391 (01) : 419 - 425
[4] Maurocalcine as a Non Toxic Drug Carrier Overcomes Doxorubicin Resistance in the Cancer Cell Line MDA-MB 231
Aroui, Sonia
Ram, Narendra
Appaix, Florence
Ronjat, Michel
Kenani, Abderraouf
Pirollet, Fabienne
De Waard, Michel
[J]. PHARMACEUTICAL RESEARCH, 2009, 26 (04) : 836 - 845
[5] Bauer C, 2005, J NUCL MED, V46, P1066
[6] Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer
Bolhassani, Azam
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2011, 1816 (02): : 232 - 246
[7] Improvement of porphyrin cellular delivery and activity by conjugation to a carrier peptide
Chaloin, L
Bigey, P
Loup, C
Marin, M
Gaelotti, N
Piechaczyk, M
Heitz, F
Meunier, B
[J]. BIOCONJUGATE CHEMISTRY, 2001, 12 (05) : 691 - 700
[8] Crombez L, 2011, METHODS MOL BIOL, V764, P59, DOI 10.1007/978-1-61779-188-8_4
[9] Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis
Curran, S
Murray, GI
[J]. EUROPEAN JOURNAL OF CANCER, 2000, 36 (13) : 1621 - 1630
[10] DEROSSI D, 1994, J BIOL CHEM, V269, P10444

← 1 2 3 4 5 6 →